Skip to main content
SpringerLink
Log in

Clozapine and Gastrointestinal Hypomotility

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Gastrointestinal hypomotility (GIH) is an under-reported but highly prevalent and potentially dangerous side effect of clozapine. In a comprehensive meta-analysis of clozapine-treated patients, the prevalence of GIH was 32%. In general, GIH has consistently been reported to have a negative impact on quality of life, and there is no reason to believe this will be different in clozapine-treated patients with therapy-resistant schizophrenia. GIH is dangerous; in a comparative review of lethal side effects of clozapine, the mortality of agranulocytosis was 2.2–4.2% compared with 15.0–27.5% for GIH. The mortality rate in our review of all published case reports of ileus was 43.7%. (Co-)Prescription of anticholinergic drugs in patients treated with clozapine should be avoided as anticholinergics are associated with increased incidence and fatality of ileus. Prevention of GIH can best be obtained by frequent and targeted questioning by the mental healthcare providers of the patients’ defecation pattern and this is therefore strongly recommended for timely detection and treatment of treatment-emergent GIH throughout clozapine treatment. Treatment approaches can be either preventive laxative prescription with every clozapine prescription in all clozapine-treated patients or targeted treatment of treatment-emergent GIH. First-line treatments of GIH are the osmotic laxative macrogol, stool softener docusate and bowel stimulant senna. As the occurrence of severe cases of GIH is not restricted to a certain treatment duration, alertness for and/or treatment of GIH is required for the whole duration of clozapine treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2000;2:CD000059 (update in: Cochrane Database Syst Rev. 2009;1:CD000059).

    Google Scholar 

  2. Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev. 2000;2:CD000966.

    Google Scholar 

  3. Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999;156:294–8.

    CAS  PubMed  Google Scholar 

  4. Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001;158:1305–13.

    Article  CAS  PubMed  Google Scholar 

  5. Conley RR, Tamminga CA, Kelly DL, et al. Treatment-resistant schizophrenia patients respond to clozapine after olanzapine non-response. Biol Psychiatry. 1999;46:73–7.

    Article  CAS  PubMed  Google Scholar 

  6. Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27:369–73.

    Article  CAS  PubMed  Google Scholar 

  7. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–63.

    Article  PubMed  Google Scholar 

  8. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. British. J Psychiatry. 2016;209:385–92.

    Article  Google Scholar 

  9. Vanasse A, Blais L, Courteau J, Cohen AA, Roberge P, Larouche A, Grignon S, Fleury MJ, Lesage A, Demers MF, Roy MA, Carrier JD, Delorme A. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand. 2016;134:374–84.

    Article  CAS  PubMed  Google Scholar 

  10. Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, Leucht S. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73:199–210.

    Article  PubMed  Google Scholar 

  11. Kane JM, Correll CU. The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry. 2016;73:187–8.

    Article  PubMed  Google Scholar 

  12. Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72(11):1439–44.

    Article  PubMed  Google Scholar 

  13. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71–93.

    Article  PubMed  Google Scholar 

  14. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol. 1994;14:119–25.

    Article  CAS  PubMed  Google Scholar 

  15. Hayes G, Gibler B. Clozapine-induced constipation. Am J Psychiatry. 1995;152:298.

    CAS  PubMed  Google Scholar 

  16. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology. 1997;8:661–7.

    Article  Google Scholar 

  17. Ellis PM, McLean RM, Harrison-Woolrych M. Clozapine: fatal ‘constipation’ more common than fatal agranulocytosis. Prescr Update. 2007;28:9.

    Google Scholar 

  18. Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69:759–68.

    Article  CAS  PubMed  Google Scholar 

  19. Flanagan RJ, Ball RY. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci Int. 2011;206:e31–6.

    Article  CAS  PubMed  Google Scholar 

  20. Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73:1307–12.

    Article  CAS  PubMed  Google Scholar 

  21. Flanagan RJ, Ronaldson KJ. Gastrointestinal hypomotility and dysphagia. In: Manu P, Flanagan RJ, Ronaldson KJ, editors. Life-threatening effects of antipsychotic drugs. London: Academic Press; 2016. p. 151–79.

    Chapter  Google Scholar 

  22. Pajouhi P, Bourgeois JA. Clozapine, fluoxetine and benztropine-associated ileus: case report. Jefferson J Psychiatry. 2007;21(1): Article 1. http://jdc.jefferson.edu/jeffjpsychiatry/vol21/iss1/1. Accessed 6 Dec 2017.

  23. Lavi E, Rivkin L, Carmon M, Reissma P. Clozapine-induced colonic obstruction requiring surgical treatment. Isr Med Assoc J. 2009;11:385–6.

    PubMed  Google Scholar 

  24. Martínez Díaz-Caneja C, González-Molinier M, Conejo Galindo J, Moreno Iñiguez M. Severe bowel ischemia due to clozapine with complete remission after withdrawal. J Clin Psychopharmacol. 2010;30:463–5.

    Article  PubMed  Google Scholar 

  25. Prieto Peraita M, Sanchez Marcosa MJ, et al. Possible ischemic colitis with clozapine. Farm Hosp. 2012;36:549.

    CAS  PubMed  Google Scholar 

  26. Shah V, Anderson J. Clozapine-induced ischaemic colitis. BMJ Case Rep 2013. https://doi.org/10.1136/bcr-2012-007933.

  27. Cam B, Tanircan MZ. Clozapine-induced paralytic ileus: a case report. Ther Adv Psychopharmacol. 2014;4:170–2.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Meyer JM, Cummings MA. Lubiprostone for treatment-resistant constipation associated with clozapine use. Acta Psychiatr Scand. 2014;130:71–2.

    Article  CAS  PubMed  Google Scholar 

  29. Osseis M, Lim C, Lahat E, Doussot A, Salloum C, Azoulay D. Hepatic venous outflow block caused by compressive fecaloma in a schizophrenic patient treated with clozapine. Drug Discov Ther. 2015;9:422–3.

    Article  PubMed  Google Scholar 

  30. Sarac H, Henigsberg N, Bagaric-Krakan L. Clozpaine-induced paralytic ileus. Psychiatr Danub. 2015;27:283–4.

    PubMed  Google Scholar 

  31. Oke V, Schmidt F, Bhattari B, Basunia M, Agu C, Kaur A, et al. Unrecognized clozapine-related constipation leading to fatal intra-abdominal sepsis—a case report. Int Med Case Rep J. 2015;8:189–92.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Castillo-Garcia IM, Maestro G, Puerta S, Ostos F, Nava P, Losada I. Clozapine-induced paralytic ileus. Actas Esp Psiquiatr. 2016;44:44–5.

    PubMed  Google Scholar 

  33. Mohan I, Wendelborn K. Constipation associated with clozapine: need for closer monitoring. Australas Psychiatry. 2016;24:97.

    Article  PubMed  Google Scholar 

  34. Peyrière H, Roux C, Ferard C, Deleau N, Kreft-Jais C, Hillaire-Buys D, et al. Antipsychotic-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2009;18:948–55.

    Article  PubMed  Google Scholar 

  35. Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016;173:166–73 (supplemental table 5 and 6).

    Article  PubMed  Google Scholar 

  36. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2012;38:592–8.

    Article  PubMed  Google Scholar 

  37. Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol. 2009;29:141–6.

    Article  CAS  PubMed  Google Scholar 

  38. Yusufi B, Mukherjee S, Flanagan R, Paton C, Dunn G, Page E, Barnes TRE. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol. 2007;22:238–43.

    Article  PubMed  Google Scholar 

  39. Shirazi A, Stubbs B, Gomez L, Moore S, Gaughran F, Flanagan RJ. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci. 2016;17:863. https://doi.org/10.3390/ijms17060863.

    Article  PubMed Central  Google Scholar 

  40. Baptista T, Carrizo E, Fernandez E, Connell L, Servigna M, Parra A, et al. Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics. Schizophr Res. 2015;166:207–11.

    Article  PubMed  Google Scholar 

  41. Every-Palmer S, Nowitz M, Stanley J, Grant E, Huthaite M, Dunn H, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine. 2016;5:125–34.

    Article  PubMed Central  Google Scholar 

  42. Berger S, Hocke M, Bär K. Gastric dysmotility in healthy first-degree relatives of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1294–9.

    Article  PubMed  Google Scholar 

  43. Rome criteria functional constipation. Attachment A, p 890, C3. http://www.romecriteria.org/assets/pdf/19_RomeIII_apA_885-898.pdf. Accessed 6 Dec 2017.

  44. Lewis SJ, Heaton KW. Stool form as a useful guide to intestinal transit time. Scand J Gastorenterol. 1997;32:920–4.

    Article  CAS  Google Scholar 

  45. Virtanen T, Eskelinen S, Sailas E, Suvisaari J. Dyspepsia and constipation in patients with schizophrenia spectrum disorders. Nord J Psychiatry. 2017;71:48–54.

    Article  PubMed  Google Scholar 

  46. Lemogne C, Nebot N, Blondon H, Roux P. Systematic prevention of severe constipation induced by antipsychotic agents: a quasi-experimental study. Eur Neuropsychopharmacol. 2016;26:1690–1.

    Article  PubMed  Google Scholar 

  47. Every-Palmer S, Ellis PM, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H. The porirua protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: a pre- and post-treatment study. CNS Drugs. 2017;31:75–85.

    Article  CAS  PubMed  Google Scholar 

  48. de Leon J, Odom-White A, Josiassen RC, Diaz FJ, Cooper TB, Simpson GM. Serum antimuscarinic activity during clozapine treatment. J Clin Psychopharmacol. 2003;23:336–41.

    Article  PubMed  Google Scholar 

  49. Bet PM, Hugtenburg JG, Penninx BW, Hoogendijk WJ. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–5.

    Article  CAS  PubMed  Google Scholar 

  50. Every-Palmer S, Newton-Howes G, Clarke MJ. Pharmacological treatment for antipsychotic-related constipation. Cochrane Database Syst Rev. 2017;1:CD011128. https://doi.org/10.1002/14651858.CD011128.pub2.

    PubMed  Google Scholar 

  51. NHG Standaard Obstipatie (Dutch) = Drug therapy of constipation. Organization of Dutch general practitioners. https://www.nhg.org/standaarden/volledig/nhg-standaard-obstipatie. Accessed 6 Dec 2017.

  52. Schwartz D. Drug Information Pharmacist, Graylands Health Service. North Metropolitan Health Service, Mental Health, Perth, Western Australia. Personal communication.

  53. Veterans’ Mates. Australian Government, Department of Veterans’ Affairs. Opioid-induced constipation: a preventable problem. https://www.veteransmates.net.au/topic-27-therapeutic-brief. Accessed 6 Dec 2017.

  54. Chukhin E, Takala P, Hakko H, Raidma M, Putkonen H, Räsänen P, Terevnikov V, Stenberg JH, Eronen M, Joffe G. In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation. Int Clin Psychopharmacol. 2013;28:67–70.

    Article  PubMed  Google Scholar 

  55. Poetter CE, Stewart JT. Treatment of clozapine-induced constipation with bethanechol. J Clin Psychopharmacol. 2013;33:713–4.

    Article  PubMed  Google Scholar 

  56. Glia A, Lindberg G. Quality of life in patients with different types of functional constipation. Scand J Gastroenterol. 1997;32:1083–9.

    Article  CAS  PubMed  Google Scholar 

  57. Damon H, Dumas P, Mion F. Impact of anal incontinence and chronic constipation on quality of life. Gastroenterol Clin Biol. 2004;28:16–20.

    Article  PubMed  Google Scholar 

  58. Wald A, Scarpignato C, Kamm MA, Mueller-Lissner S, Helfrich I, Schuijt C, Bubeck J, Limoni C, Petrini O. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007;26:227–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mental Health Organization North-Holland North, Stationsplein 138, 1703 WC, Heerhugowaard, The Netherlands

    Dan Cohen

Authors
  1. Dan Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dan Cohen.

Ethics declarations

Funding

No sources of funding were used to assist with the preparation of the review.

Conflict of interest

Dan Cohen has no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cohen, D. Clozapine and Gastrointestinal Hypomotility. CNS Drugs 31, 1083–1091 (2017). https://doi.org/10.1007/s40263-017-0481-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-017-0481-5

Search

Navigation